Dearborn Partners LLC Purchases 55 Shares of Eli Lilly and Company (NYSE:LLY)

Dearborn Partners LLC boosted its stake in Eli Lilly and Company (NYSE:LLY) by 1.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,703 shares of the company’s stock after purchasing an additional 55 shares during the quarter. Dearborn Partners LLC’s holdings in Eli Lilly and Company were worth $4,167,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. CIBC Asset Management Inc grew its stake in shares of Eli Lilly and Company by 7.9% in the 3rd quarter. CIBC Asset Management Inc now owns 206,050 shares of the company’s stock worth $182,548,000 after acquiring an additional 15,088 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co raised its holdings in Eli Lilly and Company by 1.3% in the 3rd quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 4,325 shares of the company’s stock worth $3,832,000 after purchasing an additional 57 shares in the last quarter. Sargent Investment Group LLC grew its holdings in Eli Lilly and Company by 2.5% in the third quarter. Sargent Investment Group LLC now owns 2,626 shares of the company’s stock worth $2,326,000 after purchasing an additional 63 shares during the period. Omnia Family Wealth LLC lifted its stake in shares of Eli Lilly and Company by 5.5% in the third quarter. Omnia Family Wealth LLC now owns 1,998 shares of the company’s stock worth $1,770,000 after buying an additional 105 shares in the last quarter. Finally, Kapstone Financial Advisors LLC boosted its holdings in Eli Lilly and Company by 50.2% in the third quarter. Kapstone Financial Advisors LLC now owns 766 shares of the company’s stock worth $672,000 after purchasing an additional 256 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $785.95 on Friday. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The company’s 50-day simple moving average is $888.32 and its 200 day simple moving average is $870.29. The stock has a market cap of $746.12 billion, a P/E ratio of 84.97, a PEG ratio of 3.07 and a beta of 0.43. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.66%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Analyst Ratings Changes

A number of analysts have issued reports on LLY shares. Wolfe Research started coverage on Eli Lilly and Company in a research note on Friday. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Citigroup upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Finally, Guggenheim upped their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.